Department of Neurosurgery, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.
J Neurooncol. 2012 May;108(1):141-6. doi: 10.1007/s11060-012-0808-5. Epub 2012 Mar 18.
The objective of this study is to evaluate the patterns of relapse and survival trends in patients with single brain metastases treated with post-operative adjuvant Gamma knife stereotactic radiosurgery (GKS) without whole brain radiotherapy (WBRT). Retrospective analysis of all consecutive patients who underwent GKS to the tumor cavity following resection of solitary brain metastasis was performed at a single institution. Between March 2001 and June 2010, 56 patients underwent GKS to the resection cavity following resection of intracranial metastases; no patient received pre- or post-operative WBRT as an adjuvant (salvage WBRT was permissible). The mean marginal dose was 17.1 Gy (range 14-20 Gy). The mean follow-up period was 24 months (range 3-99 months). Five patients (8.9%) had local recurrence in the immediate vicinity of the resection cavity, qualifying as "local failures", and 21 (37.5%) recurred at distant intracranial sites. Median intracranial recurrence free survival was 13 months. Median overall survival was 20.5 months. Salvage interventions were required in 26 patients, and included repeat radiosurgery in 17 patients, further surgery in two patients, and salvage WBRT in eight (14.3%; two of whom had also been locally salvaged with repeat radiosurgery) patients. As expected, avoidance of WBRT results in a high rate of intracranial failure (26/56 patients, 46%), even in well-selected patients with only single brain metastases. As anticipated, the majority of failures (21, 37.5%) are "distant intracranial", and in this well-selected cohort the local failure rate is low (5/56 patients, <9%). All patients failing intracranially (46%) are potential candidates for salvage therapies, but WBRT as salvage was utilized in only 14.3% of patients. The median intracranial relapse-free was 13 months and overall survival was 20.5 months.
本研究旨在评估术后辅助伽玛刀立体定向放射外科(GKS)治疗单纯性脑转移瘤患者的复发模式和生存趋势,而不采用全脑放疗(WBRT)。在单一机构对所有连续接受 GKS 治疗的患者进行回顾性分析,这些患者在颅内转移灶切除后均进行 GKS 治疗。2001 年 3 月至 2010 年 6 月,56 例患者在颅内转移灶切除后行 GKS 治疗切除腔;无患者接受术前或术后 WBRT 作为辅助治疗(允许挽救性 WBRT)。平均边缘剂量为 17.1Gy(范围 14-20Gy)。平均随访时间为 24 个月(范围 3-99 个月)。5 例(8.9%)患者在切除腔附近出现局部复发,符合“局部失败”标准,21 例(37.5%)患者在颅内远处部位复发。颅内无复发生存的中位数为 13 个月。总生存中位数为 20.5 个月。26 例患者需要挽救性干预,包括 17 例重复放射外科手术、2 例进一步手术和 8 例挽救性 WBRT(14.3%;其中 2 例也因重复放射外科手术而局部挽救)。正如预期的那样,避免 WBRT 会导致颅内失败率高(56 例患者中有 26 例,46%),即使是在仅有单发脑转移的精心选择的患者中也是如此。正如预期的那样,大多数失败(21 例,37.5%)是“颅内远处”,在这个精心选择的队列中,局部失败率较低(56 例患者中有 5 例,<9%)。所有颅内复发的患者(46%)都是挽救性治疗的潜在候选者,但仅 14.3%的患者接受了挽救性 WBRT。颅内无复发生存的中位数为 13 个月,总生存的中位数为 20.5 个月。